Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by Swiss National Bank
Swiss National Bank increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 285,400 shares of the biopharmaceutical company’s stock after buying an additional 10,100 shares during the period. Swiss National Bank owned 0.27% of Regeneron Pharmaceuticals worth $140,171,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after buying an additional 5,967,733 shares during the last quarter. Wellington Management Group LLP boosted its stake in Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock worth $2,377,590,000 after buying an additional 446,850 shares during the last quarter. Vanguard Group Inc. boosted its stake in Regeneron Pharmaceuticals by 4.1% in the first quarter. Vanguard Group Inc. now owns 5,121,496 shares of the biopharmaceutical company’s stock worth $1,984,630,000 after buying an additional 199,975 shares during the last quarter. State Street Corp boosted its stake in Regeneron Pharmaceuticals by 4.3% in the first quarter. State Street Corp now owns 3,380,151 shares of the biopharmaceutical company’s stock worth $1,309,861,000 after buying an additional 139,602 shares during the last quarter. Finally, Artisan Partners Limited Partnership boosted its stake in Regeneron Pharmaceuticals by 2.2% in the first quarter. Artisan Partners Limited Partnership now owns 1,933,228 shares of the biopharmaceutical company’s stock worth $749,145,000 after buying an additional 41,630 shares during the last quarter. 67.96% of the stock is currently owned by institutional investors.
Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded up 1.17% during mid-day trading on Thursday, reaching $492.84. The company’s stock had a trading volume of 212,620 shares. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55. The firm has a 50-day moving average of $487.65 and a 200 day moving average of $435.10. The firm has a market capitalization of $52.26 billion, a price-to-earnings ratio of 49.44 and a beta of 1.66.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same period in the previous year, the firm earned $2.82 earnings per share. The company’s revenue was up 21.2% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post $14.85 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/31/regeneron-pharmaceuticals-inc-regn-shares-bought-by-swiss-national-bank.html.
A number of analysts have weighed in on REGN shares. Leerink Swann reissued a “positive” rating and set a $552.00 price objective (down previously from $580.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Sanford C. Bernstein reissued an “outperform” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, May 25th. Piper Jaffray Companies reissued an “overweight” rating and set a $557.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 1st. Evercore ISI started coverage on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 16th. They set an “outperform” rating and a $605.00 price objective on the stock. Finally, BMO Capital Markets reissued a “hold” rating and set a $421.00 price objective (up previously from $412.00) on shares of Regeneron Pharmaceuticals in a report on Friday, May 5th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $495.59.
In other news, major shareholder Sanofi purchased 72,378 shares of the business’s stock in a transaction dated Friday, August 25th. The shares were bought at an average cost of $481.36 per share, for a total transaction of $34,839,874.08. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Neil Stahl sold 8,306 shares of the business’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total value of $4,423,360.30. Following the completion of the sale, the executive vice president now owns 43,950 shares in the company, valued at $23,405,572.50. The disclosure for this sale can be found here. Over the last three months, insiders acquired 374,843 shares of company stock valued at $179,928,869 and sold 131,790 shares valued at $62,940,303. 10.40% of the stock is currently owned by insiders.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.